Get the Stockscreener App
0.249
0.81%
0.002
After Hours:
.25
0.001
+0.40%
Mainz Biomed N V stock is traded at $0.249, with a volume of 1.58M.
It is up +0.81% in the last 24 hours and down -29.60% over the past month.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
See More
Previous Close:
$0.247
Open:
$0.2547
24h Volume:
1.58M
Relative Volume:
0.93
Market Cap:
$5.45M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-0.1304
EPS:
-1.91
Net Cash Flow:
$-23.84M
1W Performance:
+24.38%
1M Performance:
-29.60%
6M Performance:
-75.83%
1Y Performance:
-91.47%
1-Day Range:
$0.2326
$0.2547
1-Week Range:
$0.1852
$0.26
52-Week Range:
$0.1852
$3.3923
Mainz Biomed N V Stock (MYNZ) Company Profile
Name
Mainz Biomed N V
Sector
Industry
Phone
-
Address
-
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-21-22 | Initiated | H.C. Wainwright | Buy |
Mainz Biomed N V Stock (MYNZ) Latest News
Mainz Biomed N.V. (MYNZ) Stock: A Year of Decreases and Increases - The InvestChronicle
Technical analysis of Mainz Biomed N.V. (MYNZ) stock chart patterns - US Post News
Market Highlights: Mainz Biomed N.V. (MYNZ) Ends on a High Note at 0.25 - The Dwinnex
What is Mainz Biomed N.V. (MYNZ) Stock Return on Shareholders’ Capital? - SETE News
Is Mainz Biomed N.V. (MYNZ) a good investment opportunity? - US Post News
Market Recap: Mainz Biomed N.V. (MYNZ)’s Negative Momentum, Closing at 0.24 - The Dwinnex
Mainz Biomed (NASDAQ:MYNZ) Stock Quotes, Forecast and News Summary - Benzinga
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - GlobeNewswire
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - StockTitan
Financial Fitness Check: Examining Mainz Biomed N.V. (MYNZ)’s Key Ratios - The Dwinnex
It makes sense and dollars to buy Mainz Biomed N.V. (MYNZ) stock - SETE News
Mainz Biomed N.V. (MYNZ) deserves deeper analysis - US Post News
MYNZ Stock on the Rise: A Promising Investment - The InvestChronicle
Mainz Biomed to unveil breakthrough early cancer detection study results at DDW 2024 - MSN
Quarterly Snapshot: Quick and Current Ratios for Mainz Biomed N.V. (MYNZ) - The Dwinnex
Mainz Biomed stock plunges to 52-week low of $0.3 amid market challenges - Investing.com
Mainz Biomed stock plunges to 52-week low of $0.3 amid market challenges - Investing.com India
Behind Mainz Biomed N.V.’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Taking the lead: Mainz Biomed N.V. (MYNZ) - SETE News
MYNZ’s valuation metrics: A comprehensive analysis - US Post News
Insider’s View: Deciphering Mainz Biomed N.V. (MYNZ)’s Financial Health Through Ratios - The Dwinnex
Mainz Biomed and Liquid Biosciences Collaborate on Innovative Pancreatic Cancer Detection Tool - Vancity Buzz
An analyst sees good growth prospects for Mainz Biomed N.V. (MYNZ) - SETE News
Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool | FinancialContent Business Page - Financial Content
Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fi - News Channel Nebraska
Mainz Biomed N.V. (MYNZ) Stock: From Low to High in 52 Weeks - The InvestChronicle
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert - Yahoo Finance UK
Mainz Biomed Partners with Liquid Biosciences to Leverage - GlobeNewswire
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert - StockTitan
Mainz Biomed (NASDAQ:MYNZ) Stock Price Up 11.1% - Defense World
Mainz Biomed N.V. (MYNZ) deserves closer scrutiny - US Post News
Financial Analysis: Mainz Biomed N.V. (MYNZ)’s Ratios Unveil Key Insights - The Dwinnex
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - Yahoo Finance UK
Adversity is less terrifying than hope: Mainz Biomed N.V. (MYNZ) - SETE News
Analytical Lens: Exploring Mainz Biomed N.V. (MYNZ)’s Financial Story Through Ratios - The Dwinnex
Should investors be concerned about MYNZ’s high price-to-sales ratio? - US Post News
Get in on Mainz Biomed N.V.’s (MYNZ) buy-in window today! - SETE News
Are Mainz Biomed N.V.’shares a good deal? - US Post News
You might want to take a look at Mainz Biomed N.V. (MYNZ) now - SETE News
Mainz Biomed N.V. (MYNZ) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Mainz Biomed (NASDAQ:MYNZ) Trading 6.9% Higher - Defense World
Was Mainz Biomed N.V. (MYNZ)’s session last reading good? - US Post News
Upward Trajectory: Mainz Biomed N.V. (MYNZ) Posts a Slidee, Closing at 0.31 - The Dwinnex
Mainz Down On Data Presentation - MENAFN.COM
Take off with Mainz Biomed N.V. (MYNZ): Get ready for trading - SETE News
A stock that deserves closer examination: Mainz Biomed N.V. (MYNZ) - US Post News
Deeper Dive: Understanding Mainz Biomed N.V. (MYNZ) Through its Various Ratios - The Dwinnex
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer - Yahoo Finance UK
Investing in Mainz Biomed N.V. (MYNZ) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer - Yahoo Finance
Mainz Biomed stock plunges to 52-week low of $0.31 By Investing.com - Investing.com UK
Mainz Biomed N V Stock (MYNZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):